Procoralan (Servier) approved by European Commission for Chronic Heart Failure

Procoralan (ivabradine) from Servier Laboratories, the first selective If channel inhibitor, has been approved by the European Commission for the treatment of patients with Chronic Heart Failure. The European Commission�s decision to authorise this new indication for Procoralan followed the review of data from the SHIfT trial, the largest-ever morbi-mortality study of treatments for Chronic Heart Failure involving more than 6000 patients. It demonstrated that the treatment significantly reduced the risk of death and hospitalisation from Heart Failure, and improved the quality of life of people living with the disease. This reduction in mortality was highly significant in patients with a heart rate of 75 beats per minute (bpm), or above, for whom Procoralan is now indicated.